Pay in 4 interest-free payments of $6.34 Learn more
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10
Currently 18% of the U.S
Novo Nordisk reined in its growth forecasts for the year in its second-quarter financial results update, blaming "persistent use of compounded GLP-1s, slower-than-expected market expansion, and competition." Compounding of semaglutide should have come to a halt in the US since the drug was removed from the FDA list of medicines in short supply, but various companies continue to provide compounded GLP-1s under a loophole that allows the sale of 'personalised' formulations
It produced the highest weight loss seen in any phase 2 trial, up to 24% at the highest dose
PMC 11850796
US$ 20.86
US$ 29.41
.jpg)
US$ 29.04
US$ 23.53
US$ 29.63
US$ 29.24
US$ 26.97
US$ 20.17
